Since the 13th meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD) in Cancun, Mexico, the discussion on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits arising from their Utilization (ABS) has re-emerged, with a vengeance. The utilization through novel scientific methodologies of information and data relevant to biodiversity rather than using physical genetic resources is seen as possibly undermining the benefit sharing objective of the Convention, and therefore its integrity.
During CBD COP 14 the debate on how to deal with ABS for “Digital Sequence Information (DSI)”, as this concept is referred to under the CBD, has been intense. Divergent views were expressed on what is covered under this term and which term is best used; if and how access to and utilization of DSI should be governed, and which modalities of benefits haring would be appropriate. This issue is now being treated intersessionally by CBD, with a goal to reach an agreement at CBD COP 15 in Kunming, People’s Republic of China, within the overarching context of the post-2020 framework.
In this Webinar, that took place on September 25th at 4 PM (EEST), four experts presented different approaches and practical examples of how the issue can be handled at the national level, without necessarily waiting for a multilateral solution at the international level.
View the recording of the session here.
View here the presentation Setting the scene: ongoing legal and policy deliberations in the CBD and post-2020 context, by Hendrik Segers, Belgian National Focal Point to the Convention on Biological Diversity.
View here the presentation Understanding Digital Sequence Information (DSI) from the Nagoya Protocol perspective, Balakrishna Pisupati, Chairperson of nonprofit international think tank FLEDGE.
View here the presentation Legal measures and contractual examples addressing DSI-related issues at the national level, by Jorge Cabrera Medaglia, Professor of Environmental Law, University of Costa Rica.
View here the presentation IP considerations on biotechnological inventions comprising the use of DSI, disclosure requirements and sequence listings in patent applications, by Claudio Chiarolla, UNDP-GEF Global ABS Project Regional Specislist.
To ask questions on this topic or start a discussion click here.